Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Transatlantic tensions and the R&D debate

This article was originally published in Scrip

Executive Summary

On September 14th, Europe's Innovative Medicines Initiative, which aims to find ways of streamlining the drug development process, will hold a press conference to present its achievements to date. Approved at the end of December 2007, the IMI is a joint effort between the EU and the European industry federation EFPIA that is expected to improve the productivity of pharmaceutical and biotech R&D and give companies a keener competitive edge.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts